The patent loss of its biggest earning drug has hit Novartis’ revenues, which fell 1% in the third quarter, while operating income declining 3 per cent.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl